Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection "ILIAD 7 trial"
CI: not available
Approval Date: 06 April 2020
RevImmune's goal is to successfully trial CYT107 on COVID-19 patients as part of a global effort to treat the disease. They believe IL-7 (CYT107) can prevent patients who are in the hospital for COVID-19 from progressing to having to be treated in the ICU. A Phase II randomized clinical trial is in the process of regulatory submission, building upon the prior and ongoing clinical trials of CYT107.Back to listing